MMJ Worldwide Holdings Corp is making ready a lawsuit in opposition to the Drug Enforcement Administration (DEA) claiming the company is violating the legislation by not responding to its software to develop pharmaceutical hashish to assist its analysis. MMJ, which has two Meals and Drug Administration (FDA) investigational drug functions to analysis its developed smooth gelatin capsule in scientific trials for a number of sclerosis and Huntington’s illness, filed its software practically 5 years in the past.
MMJ alleges that the DEA’s inaction on its software is in violation of the Managed Substance Act (CSA) and the Marijuana and Cannabidiol Analysis Growth Act (MCREA), which was signed into legislation in December 2022.
Late final month, Megan Sheehan of Sheehan & Associates, representing MMJ, despatched a warning letter to DEA Deputy Assistant Administrator Matthew Strait, and DEA regulatory chief Ricardo Quintero, informing them that they had been in violation of the legislation.
Within the letter, Sheehan argued that DEA’s failure to course of MMJ’s bulk manufacturing software for nearly 5 years was a violation of each the CSA and the MCREA. She additionally argued that DEA’s angle towards the appliance, which was reported that they “would get to it once they get to it,” was in violation of DEA insurance policies and procedures, MMJ stated in a press launch.
Basically, the results for violating federal legal guidelines and laws can embody fines, penalties, and different authorized sanctions. On this case, if the DEA is discovered to have violated the CSA or the MCREA, it’s potential that the company might face fines or court-ordered injunctions, or the courtroom might order the DEA to course of MMJ’s bulk manufacturing software and take different actions to handle the company’s failure to adjust to federal legislation.
Get every day hashish enterprise information updates. Subscribe